BioCentury on BioBusiness,
Table: Post-launch report
Back to the parent article
Monday, January 13, 2014
At least four drugs approved in 2012 - Jakafi
ruxolitinib, Kalydeco ivacaftor, Stribild
elvitegravir/cobicistat/emtricitabine/tenofovir and Xtandi enzalutamide - are
on track to post 2013 sales exceeding $350 million. Below are selected drugs
approved in 2012 for which sales are disclosed. One drug from a biotech
approved in 2013 is already expected to exceed $500 million in annual sales:
Tecfidera dimethyl fumarate, which was approved for multiple sclerosis last
March (see "Top Biotech Products"). (A) 2012 approval and
nine-month sales in 2013 unless otherwise noted; (B) U.S. sales reported by
Onyx Pharmaceuticals Inc., which Amgen Inc. (NASDAQ:AMGN) acquired in
October 2013; Sales figures in millions; Sources: BCIQ: BioCentury Online
Intelligence, company documents
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]